Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FSN in acquisition of the Baggium Group
Mandate

Vinge advises FSN in acquisition of the Baggium Group

January 15, 2010

Vinge has advised funds managed by FSN Capital in connection with the acquisition of the Baggium Group. FSN Capital has offices in Oslo, Stockholm and Copenhagen and manages FSN Capitals’ funds. An independent team consisting of 17 Scandinavian investors is focusing on Nordic growth companies within the mid-cap segment which demonstrate organic or acquisition led growth potential.

FSN was advised by partners Fabian Ekeblad and Mikael Ståhl together with associates Paula Röttorp, Nils Taro Lock and Sofia Graflund. Competition law advice was provided by partner Pär Remnelid and associate Johanna Lindman.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026